Skip to content

BIOSPECIFICS TECHNOLOGIES CORP: 10-Q filed 2011-11-09

What BIOSPECIFICS TECHNOLOGIES CORP reported in its quarterly report filed 2011-11-09 (fiscal Q3 2011): 27 published measures, 78 facts as tagged in accession 0001140361-11-052400.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-09
Fiscal period
fiscal Q3 2011
Accession
0001140361-11-052400 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-3015,461,994USD
At 2010-12-3111,518,701USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-3013,828,031USD
At 2010-12-316,700,723USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-303,795,763USD
At 2010-12-312,470,852USD
At 2010-09-303,299,628USD
At 2009-12-313,950,389USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30269,836USD92
2011-01-01 to 2011-09-306,530,300USD273
2010-07-01 to 2010-09-30-484,297USD92
2010-01-01 to 2010-09-30-1,648,709USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-30758,069USD273
2010-01-01 to 2010-09-30-72,950USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-30205,872USD273
2010-01-01 to 2010-09-30234,618USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-09-30360,970USD273
2010-01-01 to 2010-09-30-812,429USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-3,363,231USD
At 2010-12-31-9,893,530USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-07-01 to 2011-09-306,362,951shares92
2011-01-01 to 2011-09-306,337,237shares273
2010-07-01 to 2010-09-306,275,758shares92
2010-01-01 to 2010-09-306,254,792shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2011-07-01 to 2011-09-307,085,945shares92
2011-01-01 to 2011-09-307,133,341shares273
2010-07-01 to 2010-09-306,275,758shares92
2010-01-01 to 2010-09-306,254,792shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-07-01 to 2011-09-300.04USD/shares92
2011-01-01 to 2011-09-301.03USD/shares273
2010-07-01 to 2010-09-30-0.08USD/shares92
2010-01-01 to 2010-09-30-0.26USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2011-07-01 to 2011-09-300.04USD/shares92
2011-01-01 to 2011-09-300.92USD/shares273
2010-07-01 to 2010-09-30-0.08USD/shares92
2010-01-01 to 2010-09-30-0.26USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-07-01 to 2011-09-30190,077USD92
2011-01-01 to 2011-09-30-2,567,328USD273
2010-07-01 to 2010-09-300USD92
2010-01-01 to 2010-09-308,067USD273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-09-30391,138USD273
2010-01-01 to 2010-09-301,710,992USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30452,100USD92
2011-01-01 to 2011-09-303,907,432USD273
2010-07-01 to 2010-09-30-501,784USD92
2010-01-01 to 2010-09-30-1,709,904USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-3012,285,835USD
At 2010-12-3110,095,258USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-301,248,168USD
At 2010-12-314,104,359USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-09-301,699,889USD
At 2010-12-311,986,125USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2011-01-01 to 2011-09-30360,447USD273
2010-01-01 to 2010-09-30418,757USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-30224,150USD92
2011-01-01 to 2011-09-30707,015USD273
2010-07-01 to 2010-09-30216,571USD92
2010-01-01 to 2010-09-301,258,187USD273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-09-3018,697,136USD
At 2010-12-3117,739,765USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-09-30122,082USD
At 2010-12-3191,925USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2011-07-01 to 2011-09-30459,913USD92
2011-01-01 to 2011-09-303,962,972USD273
2010-07-01 to 2010-09-30-484,297USD92
2010-01-01 to 2010-09-30-1,640,642USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,245,145USD92
2011-01-01 to 2011-09-304,172,687USD273
2010-07-01 to 2010-09-301,289,310USD92
2010-01-01 to 2010-09-304,969,653USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-09-3032,349USD273
2010-01-01 to 2010-09-309,770USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-7,813USD92
2011-01-01 to 2011-09-30-55,540USD273
2010-07-01 to 2010-09-30-17,487USD92
2010-01-01 to 2010-09-30-69,262USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-286,236USD273
2010-01-01 to 2010-09-30-116,965USD273

Inspect the source

Entity
BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
Captured
SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))